News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

|Videos|April 5, 2023

Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

Author(s)Kathryn E. Beckermann, MD, PhD, Moshe Ornstein, MD, MA, Mehmet Asim Bilen, MD

Drs Moshe Ornstein and Hans Hammers review data from the COSMIC-313 trial investigating ipilimumab, nivolumab, and cabozantinib for the frontline treatment of metastatic renal cell carcinoma.

Episodes in this series

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 1 Risk Stratification of Patients with Metastatic Renal Cell Carcinoma (RCC)

EP. 2 Patient Profile Presentation: A 65-Year-Old Woman With Metastatic RCC

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 3 Cabozantinib plus Nivolumab for the Frontline Treatment of Metastatic RCC: Updates From CheckMate 9ER

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 4 Considerations When Deciding Between an IO/TKI and IO/IO Treatment Regimen for a Patient With RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 5 Factoring Quality-of-Life, Liver Metastases, and Brain Metastases into Treatment Decision-Making for RCC

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 6 Treatment Approaches for Patients with RCC and Bone Metastases

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 7 Novel Doublet Combination Therapies in First-Line Metastatic RCC Treatment

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 8 Reviewing Data in Frontline Metastatic RCC Treatment from the COSMIC-313 Trial

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

EP. 9 Updates in the Adjuvant Treatment of Metastatic RCC

$EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC$

EP. 10 Patient Profile Presentation: A 47-Year-Old Male With Refractory RCC

$EP. 11 Preferred Treatment Regimens for Refractory RCC$

EP. 11 Preferred Treatment Regimens for Refractory RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 12 Best Approaches and Emerging Data in the Treatment of Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

EP. 13 Genetic Counseling for Patients with Non-Clear Cell RCC

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

Toni Choueiri, MD, Dana-Farber Cancer Institute

July 1st, 2026

FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

T-DXd for HER2+ Solid Tumors | Image Credit: © Rasi - stock.adobe.com

June 29th, 2026

T-DXd Wins EU Approval for Previously Treated, HER2+ Metastatic Solid Tumors

The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.

Trending on OncLive

Domvanalimab/Zimberelimab Plus Chemotherapy Fails to Improve OS in HER2-Negative Gastroesophageal Adenocarcinoma

Extended FOLFOX, Atezolizumab Duration Linked With Improved DFS in Stage III dMMR Colon Cancer

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases

Neoadjuvant/Adjuvant Pembrolizumab Yields EFS Benefits Regardless of Surgical Outcomes in HNSCC